Conventional treatment options for
lung cancer treatment were restricted due to non-specific nature and side effects, with this associated problem and to overcome this we had developed
lumefantrine with nano
calcium phosphate loaded
lipid nanoparticles (LF- CaP- Ls) affording pH sensitive mechanism. Herein, the present study the in vivo anti-
cancer property of LF-CaP-Ls was checked in mice models. Further, reduced
lung cancer progression of
lumefantrine with nano
calcium phosphate loaded
lipid nanoparticles (LF-CaP-Ls) treated mice were assessed by measuring the
5-methyltetrahydrofolate (
MTHF) in serum. Moreover, LF-CaP-Ls showed substantially a anticancer effect compared to that of
lumefantrine loaded
lipid nanoparticles (LF-Ls) and free
lumefantrine (LF) by exhibiting higher effects in lung
tumor bearing mice model as confirmed by reduced
tumor progression. Histopathological examination of lungs supported with H&E staining proved the reduced
tumor vasculature and reduced inflammatory cells for LF-CaP-Ls compared to that of free LF and LF-Ls. Further, visual inspection with
acetic acid test confirmed the reduced
tumor progression for LF-CaP-Ls compared to that of free LF and LF-Ls. Altogether, the overall results suggested that the developed LF-CaP-Ls may acts as a better therapeutic molecule for
lung cancer due to its maintenance of increased level of 5-MTHF levels, reduced
tumor weight. Further, hematological and biochemical parameters were measured and supports our in-vivo
therapeutic effect of LF-CaP-Ls.